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ABSTRACT
Introduction: There is common statement, that schizophrenia patients are more likely to smoke 
comparing to the total world population.
The aim of the study: The aim of this article is to find out why do schizophrenic patients smoke,
how does it affect them and what can be the cause of susceptibility to smoking.
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Material and method: The research of the scientific articles was made on a database of PubMed
and Google Scholar.
Description  of  the  state  of  knowledge:  Many different  associations  were  found during  the
research such as these describing that patients with schizophrenia have up to two to five times
higher  risk  of  developing  type  II  diabetes.  Also  patients  with  diagnosed  schizophrenia  are
characterized by low neuronal activity of the frontal  and temporal lobes of the brain. In post
mortem studies in schizophrenic patients a decrease in the number of M1 and M2 receptors in the
brain was found, mainly in the dorsal lateral part of the prefrontal cortex, hippocampus, striatum
and cingulate cortex, and decreased number of nicotinic receptors in the hippocampus, thalamus,
cingulate cortex and prefrontal cortex
The key process of undergoing of nicotine is the induction of the cytochrome P450 1A2 enzyme
(CYP  1A2),  thus  increasing  the  metabolism  of  antipsychotic  therapeutics,  e.g.  olanzapine,
clozapine what explain why usage of nicotine is told to be self-treatment in schizophrenic people.
Summary: This article gathers scientific research on the relationship between schizophrenia and
susceptibility among patients to smoking addiction and its impact on both mental and physical
health. However, not all mechanisms are known yet.
Key words: schizophrenia disease; nicotine; tobacco; smoking;
1. INTRODUCTION
Schizophrenia is a chronic disease that belongs to the group of psychoses. Although it
affects  only  1% of  the  world's  population,  it  has  serious  consequences.  The  most  important
symptoms of the disease are: an inadequate perception of the world, experiencing, receiving and
bad assessment of reality. These disorders make it very difficult for patients to function normally
in the society. Schizophrenia is most often diagnosed in young adults around 18-35 years old.
The diagnosis  is  made on the basis  of  an interview with a  doctor,  but  there are  no specific
laboratory tests that could confirm or exclude schizophrenia.
People with schizophrenia often have comorbidities. These include depression, anxiety
disorders and other psychoses. In addition, nearly 40% of patients abuse psychoactive substances.
Factors that can affect schizophrenia are genetic and environmental conditions, including
stress, sociological and neurological processes. Very high heredity of schizophrenia is reported. If
one of the parents suffers from schizophrenia, the probability of getting it by the child raises up to
18%. When both parents are sick, this probability increases even above 20% [1].
This disease consists not only of its symptoms, but also the consequences arising from
them. With such disorders as in schizophrenia, social problems are also common - in dealing with
other  people,  finding  a  job  which  increases  the  percentage  of  unemployment,  poverty  and
homelessness.  Overall,  it  is  said,  that  the  reduction  of  quality  of  life  for  people  with
schizophrenia relative to a healthy population is present [2]. The patients themselves state that
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their  level  of  education  and social  status  is  lower [3].  What  is  more,  the life  expectancy  of
schizophrenia  patients  is  also  shortened,  as  there  is  a  correlation  between schizophrenia  and
diabetes (patients with schizophrenia have up to two to five times higher risk of developing type
II diabetes) [4]. In addition, suicides are much more common in the group of patients compared
to the healthy population [5].
On  a  neurological  basis,  schizophrenia  is  distinguished  by  increased  dopaminergic
activity  in  the  mesolimbic  pathway  in  the  brain.  Due  to  the  fact  that  the  D2  dopaminargic
receptor appears to be the most important, the treatment of schizophrenia is based on blocking the
D2 receptor by classic neuroleptics or on blocking other receptors (especially 5-HT2 and α1, H1
and M1 receptors) by alternative neuroleptics. Blocking the D2 receptor is especially important
for patients complaining about excess environmental stimuli and over-estimating them. However,
it is worth noting, that pharmacological treatment of schizophrenia with neuroleptics may result
in the onset or worsening of the symptoms of pharmacologically released Parkinson's syndrome
[6].
Researchers who have studied neurology and schizophrenia have found that the volume of
the entire brain of a person with schizophrenia is smaller than that of healthy people while the
volume  of  their  left  hippocampus  is  increased.  What's  more,  there  is  evidence  that  the  left
hippocampus is the responsible mediator between the negative symptoms of the disease and the
memory of sounds and speech which is associated with the pathomechanism of schizophrenia [7].
There is increased activity of many places in the brain such as: bilateral dorsolateral prefrontal
cortex, posterior parietal cortex, anterior cingulate cortex, and supplementary motor area. This is
because of the higher density of D2 receptors. Then, because of these receptors and the use of
amphetamines with a similar  chemical  structure to dopamine,  the symptoms of schizophrenia
may get worse after consuming amphetamines.
However, in addition to increased brain activity,  sites with increased inactivation have
also been found. These are, for example: ventral medial prefrontal cortex and posterior cingulate
cortex which are part of the default mode network [8]. The default mode network is especially
active when someone does not get excess stimuli from the outside, when he relaxes, thinks about
himself, remembers the past or plans the future [9]. So if there is even an excess of stimuli, the
default mode network will then be distinguished by increased deactivation. What's more, studies
prove gray matter disorders and global functional connectivity density (gFCD), both of which are
disturbed in many places in the brains of schizophrenia patients [10].
2. MATERIALS, METHODS AND AIM
The  aim  of  this  article  was  to  find  out  the  relationships  between  smoking  tobacco  and  the
schizophrenia.  The articles were found in PubMed and Google Scholar database according to
following keywords: schizophrenia disease, nicotine, tobacco, smoking. 
3. USAGE OF PSYCHOACTIVE SUBSTANCES BY SCHIZOPHRENIA PATIENTS 
Psychoactive substances (PAS) include substances that affect the central nervous system
(CNS) by directly affecting the brain. Some of them, such as opioids and cannabioids, can be
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used in medicine as painkillers. Cannabidiol - cannabis oil, obtained from cannabis leaves has
healing properties attributed to neuroleptic drugs. It is a substance that does not belong to PAS, in
contrast to the cannabis in which it is found. It also has fewer documented side effects belonging
to extrapyramidal symptoms, which are the least desirable side effects of neuroleptics [11].
Others, however, as stimulants are used by society to exert some effect on the body. Some
of  them  can  be  used  to  stimulate  the  body  -  stimulants  (e.g.  amphetamine,  ecstasy,
methamphetamine),  and  others  as  hallucinogens  (e.g.  LSD,  hallucinogenic  mushrooms,
marijuana),  where  hallucinations  may  occur  after  consumption  larger  amounts  of  them.  The
effect depends on the receptor on which the substance is working. Thus, e.g. morphine or heroin
as opioids, by stimulating the opioid receptors of nerve cells, cause analgesia, reduction of gastric
peristalsis and bradypnoe.
Hensala et al. found that the use of LSD accelerates mental episodes and hospitalization
of patients, which is associated with about 25% of cases of this disease. The rest are responsible
for  poor  premorbid  adjustment  of  the  patient,  high  risk  associated  with  the  patient's  family
history, and abuse of other PAS [12].
PAS abuse is  very popular.  Statistically,  schizophrenia patients  use cocaine,  cannabis,
hallucinogens, inhalants, caffeine and tobacco, either significantly more or to the same extent as
healthy or ill people with other mental illnesses [13]. Statistics show that up to 60% of patients
with schizophrenia abuse the PAS [14]. Most often, because almost every fourth person (24%)
abuses  alcohol,  and  less  by  10  percentage  points  (14%)  other  PAS.  In  27.5%,  PAS  abuse
occurred before the first symptom of schizophrenia. In 37.8%, it was only after the first symptom
that the patient began to abuse the PAS. Every third patient (34.6%) started drug abuse in the
same month in which the first symptom of schizophrenia occurred [14].
What's more, research shows that from people who suffer from schizophrenia, those who
abuse one of the PAS have a higher level of intelligence, which may be associated with a higher
socioeconomic status before falling ill, as well as with higher cognitive functions of the body. In
addition, they often come from families with a higher social status and have better language skills
[15]. However it is worth noting, that patients who currently abuse PAS have a lower level of
quality of life but also fewer negative symptoms of disease than patients who do not abuse any
PAS. A very important observation in the Addington study is the fact that people who have used
PAS in the past  had an earlier  age of schizophrenia  recognized,  but  also had no personality
problems [16]. Patients in PAS look for the effect of being "high" to alleviate the symptoms of
depression and for relaxation or pleasure, while ignoring the side effects of these drugs [17].
However, if you consider how long the patient has been taking the PAS before, you can
see the relationship that the longer (more than 6 months) patients were using them, the more such
symptoms  occur,  have more pre-illness  personal  disorders,  have a greater  risk of developing
schizophrenia and other disorders [18].
The impact of PAS (alone) and schizophrenia on the brain has been examined in magnetic
resonance imaging on patients suffering from schizophrenia and on people taking PAS. Studies
have shown the effect of drugs on increased neuronal activity on the limbic lobe and prefrontal
part of the brain compared to the control group. People with long periods of drug abuse are
characterized  by the  loss  of  gray  matter  of  the  brain in  these regions.  In  turn,  patients  with
diagnosed schizophrenia are characterized by low neuronal activity of the frontal and temporal
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lobes  of  the  brain.  However,  the  largest  brain  volume  losses  occurred  in  patients  with
schizophrenia abusing PAS [19].
4. SMOKING TOBACCO BY SCHIZOPHRENIA PATIENTS 
Tobacco smoking has been seen for many years. Today, cigarettes are the most well-
known and widely available tobacco products.
According to WHO, every fourth person in the world smokes cigarette.  In connection
with the addiction,  about  7 million  people  die  every year,  of which about  890 thousand are
passive smokers who are only exposed to inhalation of cigarette smoke from smokers [20].
Cigarettes are the most common form of tobacco use. Right next to them there are cigars,
electric  cigarettes  and  others.  Cigarettes  contain tobacco  leaves  and  a  psychoactive  agent  -
nicotine  [20].  As  it  is  well  known,  smoking  these  products  harms  health  on  many  levels,
contributing to lung, larynx, as well as to tounge cancers, and other respiratory diseases. Tobacco
leaves contain, among others, tobacco glycoprotein (TGP). It is a substance that has factor XII
activating properties. This activates blood coagulation. In turn, increased coagulation may have
its effects in hematopoietic diseases and affect vascular embolism [20].
Metals that are dangerous to human health can accumulate in tobacco plants, from which
they  enter  the  human  body  during  smoking,  even  as  carcinogens.  Such  metals  can  be,  for
example, arsenic, cadmium, chromium, nickel, lead, which over the years 2009-2012 have been
isolated in cigarettes available on the Chinese market [21]. Six brands of cigarettes available in
the United States have been tested for lead-210 and polonium-210. It was confirmed that the
filters found in cigarettes significantly reduce the amount of metals and tar entering the body.
After all, the amount of lead-210 in 4 out of 6 brands of cigarettes is about twenty times higher
than the amount of this naturally occurring element even in the air [22].
Another study dealed with the difference in metals found in leaves, smoke and tobacco
ash, such as arsenic and cadmium. The same research shows that there is much more arsenic and
cadmium in tobacco ash than leaves before burning. Studies state that their quantity is not high
enough to have a harmful effect on human health, but as it is known, addictive smokers can
smoke a lot of tobacco a day, every day which could have some impact on their health as some
substances tend to accumulate in a human body [23].
An important question arises here: why do people reach for tobacco products, despite the
fact that they have negative effect on the human body? Tobacco has always been associated with
relaxation. This is why people who live in constant stress often choose them as a form of escape
from reality. A large amount of stress in human life negatively affects the well-being of people,
causing them to change their behavior and perception of the world. They often have anxiety and
excessive aggression, and contact with them is becoming increasingly difficult.  Smoking only
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allows an apparent escape from the problem, which only increases stress levels and the number of
cigarettes  smoked.  Is  it  therefore  possible  to  boldly  associate  smoking  and  stress  with  the
development of schizophrenia?
It turns out that yes, because the latest research shows that during the action of a stressor,
human genetic variation (changes in function or expression) of the CACNA1C gene that encodes
the alpha-1c subunit of Cav.2.2 type L calcium channels (LTCC) can affect the development of
neuropsychiatric  disorders  including  major  depression,  bipolar  disorder  and  schizophrenia
through serotonergic mechanisms [24]. The results of other studies confirm that stress exposure
during critical periods of life can be an important factor in the development of brain dysfunction,
which  represents  susceptibility  to  psychosis,  including  schizophrenia  [25].  Interestingly,
subsequent studies indicate  that even maternal  stress and obstetric  complications  increase the
likelihood of children developing schizophrenia later in their lives [26]. Thus, the above research
confirms the relationship between stress in human life and the development of schizophrenia.
Referring to the topic of smoking, researches indicate that smoking is very common in
schizophrenia. A meta-analysis of 42 studies from 20 countries showed that 62% of patients with
schizophrenia were smokers, so the number is much higher than in the general population (OR =
5.3).  One  explanation  for  the  high  percentage  of  smoking  in  schizophrenia  is  the  very
controversial,  so-called  "self-healing  hypothesis",  which  postulates  that  nicotine  alleviates
negative symptoms, extrapyramidal side effects (EPSE) and cognitive dysfunction by stimulating
dopaminergic  and glutaminergic  prefrontal  neurotransmission.  Despite  the controversy of this
hypothesis, studies have shown that smokers had significantly less severe EPSE compared to
non-smokers [27]. A very interesting discovery was also the fact that people with schizophrenia
have  much  more  problems  with  quitting  smoking  than  healthy  people  and  what's  more  -
compared to the general population,  people suffering from schizophrenia are four times more
likely  to  smoke  and  then  suffer  from  relatively  greater  negative  health  consequences.  This
increased smoking frequency is a potential cause of the observed increased risk among people
with schizophrenia due to cardiovascular  disease and diabetes [28]. In addition,  patients with
schizophrenia inhale  the smoke deeper  and extract  a significant  amount  of nicotine  from the
cigarette. They are highly addicted to tobacco, and their attempts to stop smoking are more likely
to fail [29].
The  above  studies  confirm  the  relationship  between  stress  and  smoking,  and  the
development  of  schizophrenia.  People  suffering  from  schizophrenia  very  often  reach  for
cigarettes and it is much more difficult for them to cope with addiction. Stress in human life has a
significant  impact  on  both  the  appearance  of  the  first  symptoms  of  the  disease  and  its
progression. People with schizophrenia often stress more than healthy people, and also fall into
the habit of smoking cigarettes more often, which in combination has a very negative impact on
their health, making them more vulnerable to cardiovascular diseases and diabetes, among others.
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5. THERAPEUTIC PROPERTIES OF NICOTINE IN SCHIZOPHRENIA
Research  has  reported  that  specific  brain  structures  -  subcortical  and  cortical  -  are
responsible for the symptoms of schizophrenia. Positive symptoms are associated with the front
part of the hippocampus, frontal peripheral region, medial prefrontal cortex, thalamus, ventral
area of Globus pallidum, striatum, black substance and abdominal epithelial region. In contrast,
negative symptoms associated with decreased frontal lobe activity - anterior, medial and dorsal
prefrontal cortex [30].
There has also been a decrease in the activity of the thalamus, in particular in the medial
dorsal nuclei. It is worth noting that the amygdala is especially important in the processing of
emotions [31]
These structures form neural circuits. The way they are organized - connected and which receptor
proteins in them, determines their function and correctness of information processing.
Classically,  schizophrenia  therapy  is  based  on  interaction  with  dopaminergic
transmission. These drugs block D2 receptors in the neuronal pathways, in this way, eliminating
positive symptoms [30].
The dopamine content is about 80% of the total catecholamines in the mammalian brain
[30].  This  catecholamine  in  the brain is  responsible for the regulation of motor  functions,  is
important  in  the  learning  and  memory  processes  and  controls  emotional  and  motivational
activities. It is located in the substantia nigra pathways; mesocorticolimbic system, often divided
into two separate parts: mesocortical and mesolimbic [30].
Cholinergic deficits observed in the course of schizophrenia and their interaction with the
dopaminergic  system,  gave  the  basis  for  the  study of  substances  modulating  the  cholinergic
transmission - muscarinic, nicotinic receptor agonists, allosteric receptors of these receptors and
acetylcholinesterase inhibitors [31].
In post mortem studies in schizophrenic patients a decrease in the number of M1 and M2
receptors  in  the  brain  was  found,  mainly  in  the  dorsal  lateral  part  of  the  prefrontal  cortex,
hippocampus, striatum and cingulate cortex, and decreased number of nicotinic receptors in the
hippocampus, thalamus, cingulate cortex and prefrontal cortex [30]. Acetylcholine in the brain is
responsible for the regulation of, inter alia, excitation and cognitive functions, such as memory
(including operational memory, spatial memory functions), learning, planning and others [31].
Moreover, in schizophrenia a strong decline in cognitive functions is observed, which is
mainly  due  to  glutamate  and NMDAR receptors.  This  occurs  with  the  equivalent  inhibitory
transmission - GABA. In the disease, this balance is disturbed in favor of inhibitory transmission
in the cognitive pathways [32].
Nicotine's mechanism of action is multifaceted. This compound modulates the activity of
dopaminergic, glutamatergic and GABAergic neurons [32]. They are destabilized in patients with
schizophrenia.
To be precise, nicotine binds to the alpha 7 receptor placed on GLU neurons, and they
activate  themselves [33]. This improves cognitive functions. For this, it directly connects to the
nAChRs  receptor,  which  is  located  on  dopaminergic  neurons,  and in  this  disease  there  is  a
reduction in its expression. But these receptors quickly desensitize, which makes it necessary to
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stop  using nicotine [33]. This explains the reason why the patients reach for a cigarette in the
morning, after waking up.
In clinical trials, nAChR agonists and antagonists such as varenicline and mecamylamine
have improved cognitive  function in people with schizophrenia  [34].  It  has been shown that
dopaminergic  neurotransmission  in  the  prefrontal  cortex  largely  depends  on  the  function  of
muscarinic  receptors  also  refreshes  the  patterns  of  dopamine-dependent  behaviours.  This  is
probably due to the effect of cholinergic neurons on pyramid cells. Acetylcholine, through the
muscarinic receptors M1 and M4, modulates the excitability of the CA1 and CA3 pyramidal cells
of the hippocampus [31].
The disease is characterized by heterogeneity, according to some it is not one unit, but a
set of symptoms. An interesting observation is that patients with schizophrenia are 3-4 times
more likely to use nicotine than in the general population [35].
The liver is the main transformation site for nicotine in the human body, because nearly
90% of  the  absorbed nicotine  is  metabolized  in  liver  cells  [36].  The  metabolic  pathways  of
nicotine  show a high degree of complexity.  Despite  the relatively  simple chemical  structure,
nicotine in the human body undergoes very complicated transformations [38]. The key process is
the induction of the cytochrome P450 1A2 enzyme (CYP 1A2), thus increasing the metabolism
of antipsychotic therapeutics, e.g. olanzapine, clozapine [33].
6. SUMMARY
Schizoferenia is a serious disease classified as psychosis. Its development is influenced by
a very large group of factors of various kinds, of which probably only a small part has been
documented and already described. The relationship between the development of schizophrenia
and tobacco  so  well  described  in  the  literature  can  be  astonishing.  When reading  about  the
probability, one should not forget that each patient is different and reacts differently to different
substances, including drugs and other environmental factors. A disturbing fact seems to be a large
percentage of people addicted to psychoactive substances in a group of people suffering from
schizophrenic  disorders.  Perhaps  the  development  of  pharmacology  and  understanding  the
mechanisms of development of schizophrenia will help reduce this percentage.
The fact that the positive and negative fields in brain disorders are disturbed is hopeful.
This can be useful not only in the context of the therapeutic effects of tobacco, but also in the
future understanding of the etiology of the disease, its prevention and effective pharmaco- and
psychotherapy.
In tobacco, in addition to the already famous nicotine, we can find a lot of compounds, most of
which are not inert to health, often showing negative and carcinogenic effects. This multitude of
substances, with some of which we may not even be realized, explains the ironic relationship of
tobacco as a predisposing factor for the development of schizophrenia, and on the other hand as a
substance that makes the sick more strongly addictive and as a therapeutic compound in relation
to schizophrenia.  Thanks to such a large variety of substances, there will certainly be those that
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have different effects. People are often afraid of the unknown, but in this case fear should be
directed to thinking about the substances that we already know. However, such a spectrum of
tobacco effects on the development and course of schizophrenia seems unbelievable, prompting
further research in this area.
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